默沙東300億美元收購談判擱淺！

藥時代

01/26

出海機會來了！尋找PCSK9小分子抑制劑產品，全球權益，目前所處階段不限。請感興趣的公司立即聯繫：藥時代BD團隊BD@drugtimes.cn藥物開發中雜質鑑定與結構解析的案例研究 | 博騰·藥時代直播間正文共：2000字預計閱讀時間：6分鐘2026年開年，一場超級併購傳聞點燃了全球生物醫藥界。據英國《金融時報》媒體透露，默沙東擬以300億美元收購Revolution，後者目前市值為227億美元。...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2606703942"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606703942\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606703942?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-26 19:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2606703942","market":"us","top_or_hot":-1,"title":"默沙東300億美元收購談判擱淺！","media":"藥時代","content":"<div>\n<p>出海機會來了！尋找PCSK9小分子抑制劑產品，全球權益，目前所處階段不限。請感興趣的公司立即聯繫：藥時代BD團隊BD@drugtimes.cn藥物開發中雜質鑑定與結構解析的案例研究 | 博騰·藥時代直播間正文共：2000字預計閱讀時間：6分鐘2026年開年，一場超級併購傳聞點燃了全球生物醫藥界。據英國《金融時報》媒體透露，默沙東擬以300億美元收購Revolution，後者目前市值為227億美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙東300億美元收購談判擱淺！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙東300億美元收購談判擱淺！\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">藥時代</strong><span class=\"h-time small\">2026-01-26 19:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>出海機會來了！尋找PCSK9小分子抑制劑產品，全球權益，目前所處階段不限。請感興趣的公司立即聯繫：藥時代BD團隊BD@drugtimes.cn藥物開發中雜質鑑定與結構解析的案例研究 | 博騰·藥時代直播間正文共：2000字預計閱讀時間：6分鐘2026年開年，一場超級併購傳聞點燃了全球生物醫藥界。據英國《金融時報》媒體透露，默沙東擬以300億美元收購Revolution，後者目前市值為227億美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b\">藥時代</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","article_id":"2606703942","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606703942","pubTimestamp":1769426529,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"據知情人士透露，默沙東與Revolution的收購談判已暫時停止，核心分歧在於價格。2026年1月7日，市場傳出艾伯維擬超200億美元收購Revolution，後者股價受此消息影響單日升逾28%。儘管艾伯維迅速下場否認，但隨後又傳出默沙東加入競逐，並將估值預期大幅抬升至300億美元區間。該藥2024年貢獻了公司近半收入、累計銷售超1500億美元的「現金牛」，一旦專利到期，將留下鉅額收入缺口。結語默沙東與Revolution的300億美元博弈雖暫告段落，但風暴眼並未消散。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4534":"瑞士信贷持仓","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4516":"特朗普概念","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","RVMD":"Revolution Medicines, Inc.","BK4585":"ETF&股票定投概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4559":"巴菲特持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4550":"红杉资本持仓","BK4588":"碎股","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","MRK":"默沙东","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC"},"translate_title":"Merck's $30 billion acquisition negotiations run aground!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1.96,"RVMD":1.94},"content_text":"出海機會來了！尋找PCSK9小分子抑制劑產品，全球權益，目前所處階段不限。請感興趣的公司立即聯繫：藥時代BD團隊BD@drugtimes.cn藥物開發中雜質鑑定與結構解析的案例研究 | 博騰·藥時代直播間正文共：2000字預計閲讀時間：6分鐘2026年開年，一場超級併購傳聞點燃了全球生物醫藥界。據英國《金融時報》媒體透露，默沙東擬以300億美元收購Revolution，後者目前市值為227億美元。推薦閲讀：收購傳聞又起！默沙東擬300億美元收購這家公司…然而不足一個月，這場繼輝瑞收購Seagen的超級併購傳聞卻又傳出戲劇性轉折。據知情人士透露，默沙東與Revolution的收購談判已暫時停止，核心分歧在於價格。估值博弈下的暫時休兵回顧此次收購傳聞，算得上一波三折。2026年1月7日，市場傳出艾伯維擬超200億美元收購Revolution，後者股價受此消息影響單日升逾28%。儘管艾伯維迅速下場否認，但隨後又傳出默沙東加入競逐，並將估值預期大幅抬升至300億美元區間。截圖來源：Revolution消息一出便引發行業震動，KRAS賽道迎來超級狂歡。Erasca等相關企業股價應聲大漲，國內勁方醫藥、加科思等藥企也順勢走出連續上漲行情，再次推動了KRAS作為PD-1之後最大癌症靶點的黃金地位。雖然目前的談判已經擱置，但這並不意味着交易徹底終結，雙方仍有可能重啓談判，或者會出現其他競標者介入。此前，默沙東首席執行官雖強調公司主要關注150億美元以下的交易，但也對更大規模交易持開放態度，這為未來的變數留下了伏筆。Revolution為何值300億美元？Revolution的資本溢價，根植於其對RAS蛋白的革命性突破。RAS突變被認為胰腺癌、肺癌、結直腸癌等多個癌種的核心驅動因子，長期被視為「不可成藥」。2013年，Kevan Shokat實驗室首次報道KRAS G12C突變的「口袋」，打破神話。而Revolution科學顧問委員會正由Shokat領銜，為其技術背書。管線方面，Revolution領先資產Daraxonrasib（RMC-6236）是一種口服的泛RAS抑制劑，能直接作用於處於激活（ON）狀態的RAS蛋白，阻斷RAS與下游信號蛋白的結合。該藥物已進入四項全球III期臨床研究，針對胰腺導管腺癌（PDAC）和RAS突變NSCLC。其中，針對胰腺癌的關鍵研究數據預計於2026年夏季公布，且已獲得FDA的優先審評券資格，有望在2026年加速獲批。此外，Revolution的另一款KRAS G12D抑制劑RMC-9805，也將於今年啓動兩項三期臨床試驗，分別針對一線胰腺癌、一線肺癌；還有一款G12C選擇性抑制劑Elironrasib臨床數據可觀，單藥治療I期研究數據顯示，在既往接受過免疫治療和化療、但未使用過KRAS G12C抑制劑治療的NSCLC患者中，每日兩次、每次200毫克劑量的治療組，ORR達到56%。更關鍵的是，Revolution的RAS抑制劑與默沙東王牌K藥（Keytruda）聯用潛力已現端倪。Revolution的RMC-6236與Elironrasib兩款候選藥物，均在臨床研究中觀察到與PD-1抑制劑聯用的潛力。例如，Elironrasib聯合K藥在PD-L1高表達NSCLC患者中初步ORR達100%，這一點尤為關鍵。默沙東的「併購焦慮」默沙東願意為Revolution一擲千金，主要源於迫在眉睫的「專利懸崖」。默沙東最為核心的超級重磅炸彈Keytruda（K藥）將於2028年失去關鍵市場獨佔權。該藥2024年貢獻了公司近半收入、累計銷售超1500億美元的「現金牛」，一旦專利到期，將留下鉅額收入缺口。儘管默沙東已通過多項交易擴充管線，但市場對其未來增長動能依然深表擔憂，這直接導致其股價在2025年於MNC中表現一般。因此，尋找能夠填補空白、甚至締造下一個傳奇的資產，已成為默沙東的戰略急務。而Revolution，正是其眼中最理想的「解題方案」之一。一方面，Daraxonrasib若成功，可與K藥形成「雙保險」，延長Keytruda生命周期；另一方面，300億美元估值僅相當於Keytruda一年收入，但若能鎖定未來腫瘤市場，性價比遠超競品。值得一提的是，儘管Revolution估值高，但KRAS賽道的爭議遠未平息。Revolution採用覆蓋KRAS/HRAS/NRAS的泛抑制策略，但動物模型顯示，同時抑制三家族RAS可能導致致命毒性。當前市場更關注「僅KRAS抑制」路線的安全性驗證，Revolution需證明其泛抑制劑在有效性和毒性間取得平衡。結語默沙東與Revolution的300億美元博弈雖暫告段落，但風暴眼並未消散。這場談判不僅是對一家生物技術公司價值的定價，更是對KRAS賽道未來商業潛力的預演，以及對整個製藥行業在創新轉型和生存壓力下戰略膽魄的考驗。無論交易最終花落誰家，其結果都將在未來5-10年深刻影響全球腫瘤治療的研發格局與市場競爭態勢。Revolution的故事，遠未到終章。封面圖/摘要圖來源：即夢AI國內首個DAC出海合作達成！2026-01-26APSB | 周慶同/王明偉團隊揭示Gq和Gi蛋白偶聯的GLP-1受體結構特徵2026-01-26馬斯克宣佈2026年進入腦機接口量產時代！三體人讚好2026-01-24破局「十年滯後」：度普利尤單抗如何穿越兒童用藥的\"深水區\"？2026-01-23","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}